Subscribe
shutterstock_393927661_marbury
marbury / Shutterstock.com
22 July 2022Big PharmaStaff writer

Competition watchdog fines big pharma duo £70m

The pair are rapped for overcharging the NHS | Unfair prices for an epilepsy drug lasted four years | Costs leapt from £2m to £50m in one year after the companies' “illegal exploitation” of market position.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK regulators no longer exempt from paying successful parties' costs
26 May 2022   The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.
Big Pharma
CMA costs case improves access to justice
30 June 2022   The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.
Big Pharma
Swiss watchdog investigates Novartis over patent use
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
UK regulators no longer exempt from paying successful parties' costs
26 May 2022   The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.
Big Pharma
CMA costs case improves access to justice
30 June 2022   The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.
Big Pharma
Swiss watchdog investigates Novartis over patent use
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

More on this story

Big Pharma
UK regulators no longer exempt from paying successful parties' costs
26 May 2022   The UK Supreme Court has ruled that regulators such as the Competition and Markets Authority should be required to pay the costs of a party successfully appealing against one of their infringement decisions.
Big Pharma
CMA costs case improves access to justice
30 June 2022   The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.
Big Pharma
Swiss watchdog investigates Novartis over patent use
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility